NC-LENOVO
28.8.2024 15:01:27 CEST | Business Wire | Press release
Lenovo (HKSE: 992) (ADR: LNVGY), the global technology powerhouse, is offering Lenovo Hybrid Cloud Advisory Services to help enterprises simplify the complexity of hybrid cloud design and create implementation-ready, future-proofed plans in as few as six weeks. Lenovo leverages four decades of experience helping global CIOs ease cloud and hybrid cloud challenges, including demands associated with emerging AI-related workloads. With the new services, Lenovo expert consultants guide enterprises through hybrid cloud needs, accelerating time to value, improving cost efficiency, and building flexibly scalable foundations.
The new era of AI is hybrid, and today’s IT organizations are converting their raw data into actionable insights with hybrid cloud solutions that are capable of harnessing data, no matter where it lives. Lenovo hybrid cloud solutions boost AI performance and agility by delivering more compute and faster memory when and where it’s needed, offering a full-stack portfolio and purpose-built solutions that are specific to each customer and use case. To support AI optimization, Lenovo Hybrid Cloud Advisory Services help design a cloud approach customized for today, and ready to flexibly scale and adapt to future needs.
“At a time when the need for modern infrastructure and solutions has never been greater, IT is challenged to evolve cloud implementations. This is evident in our most recent Lenovo global CIO report in which 82% of respondents marked cloud transformation as challenging,” said Dale Aultman, Vice President & General Manager, Hybrid Cloud Services at Lenovo Group. “We introduced Lenovo Hybrid Cloud Advisory Services to simplify cloud design strategies and pave the way for AI implementations. We bring a global team of trusted experts to help our customers develop future-proofed, tailor-made solutions to rapidly modernize hybrid clouds and ultimately deliver better business outcomes.”
Many organizations need to modernize or update their hybrid clouds due to changing business needs, spiraling costs, or performance issues. In fact, Lenovo’s third annual global CIO report found that 29% of respondents still find cloud transformation a top priority, behind AI implementation, cybersecurity, and data privacy. Demand for data center capacity continues to grow and, with increasing interest in AI, is also accelerating. IT leaders are concerned about meeting this demand due to challenges around qualified staff, procuring equipment, forecasting future requirements and energy efficiencies. Changing licensing models are also generating disruption and requiring IT leaders to lean on partners.
“Successful hybrid cloud strategy and design is imperative for enterprises, yet the underlying complexity involved cannot be understated,” said Steven Dickens, Futurum Group. “According to our research, hybrid is 2x the size of public cloud when it comes to deployment modalities for AI, therefore the need for flexibility and futureproofing becomes critical. Partnering with experts, such as Lenovo, will be the smart path forward for many enterprises.”
Lenovo Hybrid Cloud Advisory Services offers customized, strategic expertise, and a trusted partner to manage the complexity of hybrid cloud design. Lenovo experts help turn hybrid cloud vision into reality with better outcomes using customer assessment, proven methodologies, and strategic advice and approach recommendation. Lenovo’s tech-agnostic expertise, deep industry alliances and partnerships, pre-validated solutions, and experience in every aspect of hybrid cloud creation provide clear value while helping future-proof an organization’s hybrid cloud. Customer benefits include:
- Speed/Time to value
- Holistic: Cloud/software/infrastructure expertise from single provider
- End-to-end expertise
- Engineering quality
- Global presence
Lenovo Hybrid Cloud Advisory Services features a breadth of offerings that are now available, expanding Lenovo’s advisory services capabilities and complementing Lenovo’s AI services portfolio. Channel availability will launch in September 2024.
For more information regarding Lenovo Hybrid Cloud Advisory Services visit here.
About Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (data center, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828812342/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
